Literature DB >> 7651740

Specific DNA binding by different classes of human p53 mutants.

N Rolley1, S Butcher, J Milner.   

Abstract

The p53 protein is a multifunctional transcription factor which orchestrates cellular responses to DNA damage, so helping to conserve genomic stability. It may also regulate genes involved in intercellular signalling, such as thrombospondin, a negative regulator of angiogenesis and metastatic spread. Activation of p53 target genes requires sequence-specific DNA binding, a function which maps to the central core of the protein. Missense point mutations within this domain inactivate p53 tumour suppressor function and involve either (i) DNA contact residues, or (ii) residues important for conformational structure. Using in vitro techniques we have analysed seven DNA contact mutants and 17 structural mutants known to occur in cancer. We show that DNA contact mutants can be carried into specific DNA interaction when co-expressed with wild type protein. For structural mutants, 9/17 retained DNA binding capacity and, with one exception, DNA binding correlated with conformational flexibility of the mutant protein. The exception was Asp281, which appeared essential for DNA interaction, probably due to its ability to form salt bridges with DNA contact residues Arg273 and Arg280. We suggest that different classes of p53 mutant may prove amenable to different strategies for restoration of wild type tumour suppressor function as means of anti-cancer therapy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7651740

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  24 in total

1.  ΔNp63α regulates keratinocyte proliferation by controlling PTEN expression and localization.

Authors:  M K Leonard; R Kommagani; V Payal; L D Mayo; H N Shamma; M P Kadakia
Journal:  Cell Death Differ       Date:  2011-06-03       Impact factor: 15.828

2.  Resistance to rabies virus infection conferred by the PMLIV isoform.

Authors:  Danielle Blondel; Sabrina Kheddache; Xavier Lahaye; Laurent Dianoux; Mounira K Chelbi-Alix
Journal:  J Virol       Date:  2010-08-11       Impact factor: 5.103

3.  p53 DNA binding can be modulated by factors that alter the conformational equilibrium.

Authors:  K G McLure; P W Lee
Journal:  EMBO J       Date:  1999-02-01       Impact factor: 11.598

4.  Mutant p53 disrupts MCF-10A cell polarity in three-dimensional culture via epithelial-to-mesenchymal transitions.

Authors:  Yanhong Zhang; Wensheng Yan; Xinbin Chen
Journal:  J Biol Chem       Date:  2011-03-22       Impact factor: 5.157

5.  Wild-type but not mutant p53 activates the hepatocyte growth factor/scatter factor promoter.

Authors:  A M Metcalfe; R M Dixon; G K Radda
Journal:  Nucleic Acids Res       Date:  1997-03-01       Impact factor: 16.971

6.  Proteolysis by calpains: a possible contribution to degradation of p53.

Authors:  M Pariat; S Carillo; M Molinari; C Salvat; L Debüssche; L Bracco; J Milner; M Piechaczyk
Journal:  Mol Cell Biol       Date:  1997-05       Impact factor: 4.272

7.  Database of p53 gene somatic mutations in human tumors and cell lines: updated compilation and future prospects.

Authors:  P Hainaut; T Soussi; B Shomer; M Hollstein; M Greenblatt; E Hovig; C C Harris; R Montesano
Journal:  Nucleic Acids Res       Date:  1997-01-01       Impact factor: 16.971

8.  Analysis of the p63 gene in classical EEC syndrome, related syndromes, and non-syndromic orofacial clefts.

Authors:  L L Barrow; H van Bokhoven; S Daack-Hirsch; T Andersen; S E C van Beersum; R Gorlin; J C Murray
Journal:  J Med Genet       Date:  2002-08       Impact factor: 6.318

Review 9.  Response of tumour cells to hypoxia: role of p53 and NFkB.

Authors:  J A Royds; S K Dower; E E Qwarnstrom; C E Lewis
Journal:  Mol Pathol       Date:  1998-04

10.  Effects of mutant p53 expression on human 15-lipoxygenase-promoter activity and murine 12/15-lipoxygenase gene expression: evidence that 15-lipoxygenase is a mutator gene.

Authors:  U P Kelavkar; K F Badr
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-13       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.